Applied Clinical Trials, July/August 2019 Issue (PDF)
Regenerative Medicine Companies Pursue Unique Regulatory Pathways
Tackling the Challenges of Transitioning to RBM
Too Fast or Too Slow? Debate Intensifies over FDA Regulatory Requirements
Challenges Emerge from Low NASH Awareness
Zeroing in on Real Patient-Centric Metrics
The Growing Threat to Clinical Trials and Research in a Fracturing Europe
The Gene Therapy Product Development Process
Adopting eISF for Remote Quality Oversight of Trials
The Cancer Trial Paradox: Too Few Patients to Some, Too Few Trials to Others